pancreatic cancer

News

Merus grabs first-in-class US approval for NRG1 cancer drug

Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer

News

Alligator slashes workforce and pares down its pipeline

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce.

News

Alligator pancreatic cancer drug 'nearly doubles' survival

Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<

News

FibroGen scientist records data manually into a notebook

FibroGen wields axe as pancreatic cancer drug is canned

FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.

News

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients.

News